BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15668751)

  • 1. Alefacept is well tolerated in patients with chronic plaque psoriasis.
    Gottlieb AB
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():14-9. PubMed ID: 15668751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
    Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
    Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alefacept: a review of the literature and practical guidelines for management.
    Hodak E; David M
    Dermatol Ther; 2004; 17(5):383-92. PubMed ID: 15379773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical update on alefacept: consideration for use in patients with psoriasis.
    Gade JN
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis.
    Krueger GG
    Expert Opin Biol Ther; 2002 Apr; 2(4):431-41. PubMed ID: 11955280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
    Ellis CN; Krueger GG;
    N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
    Lowe NJ; Gonzalez J; Bagel J; Caro I; Ellis CN; Menter A
    Int J Dermatol; 2003 Mar; 42(3):224-30. PubMed ID: 12653922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alefacept for chronic plaque psoriasis: a selective therapy with long-lasting disease remissions and an encouraging safety profile.
    Leone G; Rolston K; Spaulding G
    Dermatol Nurs; 2003 Jun; 15(3):216-20, 224-5; quiz 226. PubMed ID: 12875010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
    Moul DK; Routhouska SB; Korman NJ
    J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
    Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
    Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases.
    Thaçi D; Pätzold S; Kaufmann R; Boehncke WH
    Br J Dermatol; 2005 May; 152(5):1048-50. PubMed ID: 15888169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
    Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
    J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alefacept: an expert review concerning the treatment of psoriasis.
    Langley RG; Cherman AM; Gupta AK
    Expert Opin Pharmacother; 2005 Oct; 6(13):2327-33. PubMed ID: 16218892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and use of alefacept to treat psoriasis.
    Krueger GG; Callis KP
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alefacept: a novel biologic in the treatment of psoriasis.
    Liu CM; McKenna JK; Krueger GG
    Drugs Today (Barc); 2004 Dec; 40(12):961-74. PubMed ID: 15645008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alefacept.
    Frampton J; Wagstaff A
    Am J Clin Dermatol; 2003; 4(4):277-86; discussion 287. PubMed ID: 12680805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.
    Krueger GG
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():17-24. PubMed ID: 12795771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alefacept: potential new therapy for patients with moderate-to-severe psoriasis.
    Shukla VK
    Issues Emerg Health Technol; 2003 Apr; (45):1-4. PubMed ID: 12680422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.